Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NGM's lead candidate positive in PhII liver disease trial

This article was originally published in Scrip

Executive Summary

Phase II data from NGM Biopharmaceuticals' NGM282 in patients with primary biliary cirrhosis (PBC) show the product demonstrated significant, dose-dependent and clinically meaningful reductions in alkaline phosphatase (ALP), a primary indicator of disease activity, as well as reductions in 7α-Hydroxy-4-cholesten-3-one (C4), a marker of bile acid synthesis. NGM282 did not exacerbate pruritus, a common symptom of PBC, NGM noted. The privately held company said the data suggest that NGM282, an engineered protein variant of the human hormone FGF19, is a potent regulator of bile acid synthesis. The product was not included in NGM's recent deal with Merck & Co, where the big pharma spent $96m up front and a further $106m to own a 15% share in NGM plus at least $250m in R&D funding during the next five years. The transaction gave Merck an initial license for NP201, NGM's preclinical candidate for diabetes, obesity and non-alcoholic steatohepatitis (NASH). NGM raised $50m in series C round in mid-2013 – bringing its venture capital total since 2008 to about $130m.

You may also be interested in...

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts